Jan 19, 2026
Summary In the seven major markets (7MM: US, EU4, UK, Japan), diagnosed cases of CVI reached ~17 million in 2024. Prevalence is projected to grow at a 1.4% CAGR, reaching ~20 million by 2034, driven by aging populations, obesity, sedentary lifestyles, and improved diagnostics. Endovenous laser ablation...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper